Trial Profile
A Phase I Study of DT2219ARL (IND100780), a Bispecific Chain Immunotoxin for the Treatment of CD19(+), CD22 (+) B-Lineage Leukemia or Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs DT2219ARL (Primary)
- Indications B-cell leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 30 May 2019 Topline consolidated results of two phase I/II trials (NCT00889408 and NCT02370160) presented in a GT Biopharma media release.
- 07 Aug 2017 According to a GT Biopharma media release, company changed its name from OXIS International to GT Biopharma.
- 09 Feb 2017 Status changed from active, no longer recruiting to completed.